IMMX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Immix Biopharma Inc (IMMX) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The stock shows strong potential due to positive analyst ratings, a promising pipeline with its NXC-201 therapy, and significant upside potential. While the financials are still in the red, the company's progress in clinical trials and favorable sentiment from analysts outweigh the risks for a long-term investor.
The technical indicators suggest a bullish trend. The MACD is positively expanding, the RSI is neutral at 63.326, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its resistance level of 9.996, indicating potential for upward movement.
Analysts have consistently raised price targets, with the latest targets ranging from $15 to $
NXC-201, the company's BCMA-directed CAR-T therapy, has shown strong clinical data and could become the first approved therapy for relapsed/refractory AL amyloidosis.
Significant upside potential with a bull-case scenario of 415% as per Citizens.
Encouraging sentiment from key opinion leaders and analysts.
The company is not yet profitable, with a net income of -$10.69M in Q4
No recent news or significant insider/hedge fund trading trends to provide additional confidence.
The stock's short-term trend indicates limited movement in the next week, with only a 0.02% expected gain.
In Q4 2025, the company reported no revenue growth, but net income improved by 122.11% YoY to -$10.69M. EPS also improved by 68.75% YoY to -0.27. While the company remains unprofitable, the improvement in net income and EPS is a positive sign.
Analysts are overwhelmingly positive on IMMX. Mizuho, H.C. Wainwright, Morgan Stanley, and Citizens all have Outperform or Buy ratings, with price targets ranging from $15 to $23. Analysts highlight the company's improved cash position, strong clinical data, and significant market opportunity for NXC-201 as key drivers for their optimism.
